Vangoo Capital
Overview
Vangoo Capital Partners was established in China in 2008, as a wholly owned subsidiary of Ant Capital Partners, one of Japan's leading private equity investment institutions . After a management buyout in 2011, Vangoo began to operate independently . Vangoo focuses on the huge market potential and the rapid growth of new enterprises in China and closely grasps the rhythm of the nationalization of high-end technology and industrialization of innovative technology during the Chinese industrial restructuring process . Vangoo has formed its own core competitiveness in the area of industrial investment . Vangoo's range of investments covers the high-growth areas of medical, Internet, consumer products, high-tech, and new energy .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Sanegene Bio | Dec 2025 | Series B | Co-investor |
| Beijing CTSmed Co., Ltd. | Nov 2022 | Pre Seed | Co-investor |
| Suzhou Qianji Intelligent Technology Co., Ltd. | Apr 2022 | Series D | Co-investor |
| Sanegene Bio | Aug 2021 | Series A | Co-investor |
| Bubi (Beijing) Network Technologies Co., Ltd. | Nov 2017 | Series A | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.